

# IDO Activity As A Marker Of Tumor Immune Escape And IDO Inhibitors As A Means Of Enhancing T Cells Response To Antigen Specific Vaccine

View U.S. Patent Application Publication No. US-2022-0218809 in PDF format.

### WARF: P190013US02

Inventors: Douglas McNeel, Christopher Zahm, Laura Johnson

### The Invention

The present invention from UW Madison researchers provides compositions and methods of treating prostate cancer using a combination of a DNA vaccine, PD-1 inhibitor and an IDO inhibitor. Further, methods of measuring IDO activity as a way to identify a subpopulation of subjects with prostate cancer that may benefits from the treatment methods described herein are provided.

## **Additional Information**

### For More Information About the Inventors

• Douglas McNeel

#### **Tech Fields**

• Therapeutics & Vaccines : Vaccines

For current licensing status, please contact Andy DeTienne at adetienne@warf.org or 608-960-9857

We use cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the storing of cookies and related technologies on your device. See our privacy policy

